RJFSA
SUPN icon

Raymond James Financial Services Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,749
Closed -$404K – 2886
2018
Q2 		$404K Buy
+6,749
New +$350K ﹤0.01% 2021

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Raymond James Financial Services Advisors's SUPN Position: Q3 2018 in Review

Raymond James Financial Services Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 6,749 shares — an estimated $404K sold.

Raymond James Financial Services Advisors first reported a position in SUPN in Q2 2018 and held it in 1 quarter. The position peaked at $404K in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

  • Raymond James Financial Services Advisors reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 6,749 Supernus Pharmaceuticals shares in Q3 2018, an estimated $404K.
  • Raymond James Financial Services Advisors first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Supernus Pharmaceuticals position peaked at $404K in Q2 2018.
  • 288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.